Medical/Pharmaceuticals
Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient inEurope in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being developed for ...
2021-06-22 13:15
1585
Berry Oncology Partners with Alibaba Health to Create China's Early Cancer Screening Ecosystem
BEIJING, June 21, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company of Berry Genomics, and Alibaba Health have signed a strategic agreement to jointly build a comprehensive cancer screening and prevention ecosystem based on a strategy that combines internet connectivity, early can...
2021-06-21 21:00
1892
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment ofAndrew Zhu, MD, PhD, to the Company's ...
2021-06-21 20:00
7841
TIAN RUIXIANG Holdings Ltd Steps into Healthcare Management Industry
BEIJING, June 21, 2021 /PRNewswire/ -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance broker, announced today that the Company plans to explore and expand into healthcare management industry. The Company plans to cooperate with governments, insurance companies,...
2021-06-21 20:00
23297
Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test
PISCATAWAY, N.J. and SINGAPORE, June 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, annou...
2021-06-21 19:27
8860
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.
NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...
2021-06-20 21:00
3255
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...
2021-06-18 17:12
14191
RBC Expands Global Youth Charity Program - RBC Charity Day for the Kids
* Virtual celebrations held by RBC Capital Markets employees in Canada, U.S., U.K.,France, Germany, Japan, Hong Kong, Australia, Barbados and Bahamas * US$5 million donated to over 50 charities worldwide SYDNEY, June 18, 2021 /PRNewswire/ -- As part of a global charitable initiative called RBC...
2021-06-17 20:00
2225
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
2021-06-17 15:41
14330
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...
2021-06-17 11:31
14572
Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility
-- New Features in Release 11 Combined with Expanded Indication for Mixed Dentition to Treat Kids and Teens is a Home Run for Doctors -- BREA, Calif., June 16, 2021 /PRNewswire/ -- Ormco Corporation, a global leader of orthodontic solutions, today announced it has received FDA clearance to tre...
2021-06-16 20:45
1862
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...
2021-06-16 13:08
8904
Smith+Nephew launches Real Intelligence and CORI™ Surgical System, next generation robotics platform, in Australia and New Zealand
LONDON, June 16, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its Real Intelligence suite of enabling technology solutions including its next generation robotics platform, the CORI Surgical System, inAustralia and New ...
2021-06-16 06:00
12733
VNTC confirms Dong-A ST its sole distributor of scoliosis brace Spinamic in South Korea
SEOUL, South Korea, June 15, 2021 /PRNewswire/ -- VNTC, a MedTech company, announced onJune 15 its signing of a Korean distributorship contract with Dong-A ST. The two companies are now able to provide a wide range of services both at home and abroad through mutual cooperation in sales and market...
2021-06-16 00:00
3539
Frontera Therapeutics Starts GMP Manufacturing Facility Construction
SUZHOU, China, June 15, 2021 /PRNewswire/ -- On June 9, 2021, Frontera Therapeutics Co., Ltd. ('Frontera') held a groundbreaking ceremony to start the construction of its Suzhou facility in bioBAY of Suzhou Industrial Park (SIP), Jiangsu, China. President of Suzhou Frontera, Dr. Xinyan Li, hosted ...
2021-06-15 23:32
2051
BIO Digital Taiwan Day will be held on June 22
TAIPEI, June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt their practices and embrace digital transformation - and now, as vaccines become more available in the developed countries, it is time to look into the future...
2021-06-15 23:00
2523
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with theJoan & Sanford I Weill Medical College of Cornell University in the United States, to launch ...
2021-06-15 22:00
11508
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...
2021-06-15 08:46
1570
Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab
DUBAI, UAE, June 14, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health. The live in-person event is scheduled to take place from 21 to24 June, 2021 a...
2021-06-14 15:00
2571
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...
2021-06-14 06:00
2445
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7507
